Research programme: Ubiquitin ligase modulators - Accutar Biotechnology
Alternative Names: E3 ligase modulators- Accutar BiotechologyLatest Information Update: 06 Oct 2021
At a glance
- Originator Accutar Biotechnology
- Class
- Mechanism of Action Enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 28 Sep 2021 Early research in Unspecified in USA (unspecified route) before September 2021 (Accutar Biotechnology pipeline, September 2021)